AbbVie enters a strategic agreement worth up to $2.54 billion with Germany-based Disco Pharmaceuticals to develop next-generation AND-gated bispecific therapeutics for solid tumors. Disco receives $40 million upfront plus up to $2.5 billion in potential milestones and tiered royalties. The technology aims to selectively target cancer cells expressing two specific proteins simultaneously to spare healthy tissue. Disco plans to choose a development candidate for lung or colorectal cancer in late 2027.
AbbVie and Disco Pharmaceuticals partnership details
- ▪AbbVie agreed to pay up to $2.54 billion to develop cancer treatments with Germany-based Disco Pharmaceuticals
- ▪Under AbbVie's up to $2.54 billion agreement with Disco Pharmaceuticals, Disco is eligible for tiered royalties on worldwide net sales, while AbbVie retains exclusive rights to license selected programs following research completion
AND-gated bispecific technology and Disco's pipeline
- ▪Disco Pharmaceuticals CEO Mark Manfredi stated that Disco Pharmaceuticals will select a development candidate in the second half of 2027
- ▪Germany-based Disco Pharmaceuticals has been developing AND-gated therapies targeting small-cell lung cancer and colorectal cancer
- ▪AND-gated bispecific therapeutics are designed to recognize cancer cells only when two target proteins are present simultaneously, which may reduce damage to healthy tissue
Pharmaceutical industry focus on bispecific cancer therapies
- ▪In January 2026, AbbVie paid RemeGen $650 million upfront for rights outside China to a bispecific medicine targeting solid tumors
- ▪Pharmaceutical companies Bristol Myers Squibb, Pfizer, and Merck have increased their focus on bispecific antibody cancer therapies
Story comments
Loading comments…